Bumrungrad Hospital Pub Co (BH) Earnings Surpass Estimates with 1Q EPS Beat

Bumrungrad Hospital Pub Co on Smartkarma

Analysts on Smartkarma are upbeat about Bumrungrad Hospital Pub Co‘s performance, as highlighted by Tina Banerjee in her recent reports. In one analysis titled “Bumrungrad Hospital (BH TB): Record High Performance in 2023; Middle-East Performance Recovers,” Banerjee notes a significant 23% revenue growth driven by various patient segments. The company reported expanding margins, with revenue from Middle-East patients increasing by 23% in the second half of 2023 compared to the first half. Despite concerns about unrest in the Middle-East impacting the stock, the overall performance of Bumrungrad Hospital looks promising.

In another report by Tina Banerjee titled “Bumrungrad Hospital (BH TB): Strong 3Q23 Performance; Middle-East Tension Plays Spoilsports,” the analyst highlights an 18% year-over-year revenue growth in the third quarter of 2023, led by Thai and expat patients. EBITDA and profit after tax (PAT) reached record highs, showcasing the company’s financial strength. However, the ongoing tension in the Middle-East has dampened investor sentiment, leading to a noticeable decline in Bumrungrad Hospital’s shares. Despite this setback, the strong performance and growth in key patient segments indicate a positive outlook for the company’s future.

A look at Bumrungrad Hospital Pub Co Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

With a strong focus on growth and resilience, Bumrungrad Hospital Pub Co is positioned well for the long-term. Smartkarma Smart Scores indicate that the company excels in these areas, scoring a 5 in both Growth and Resilience. The Hospital, located in Bangkok, boasts international standard medical care facilities, including 554 beds for inpatients and 125 clinic examination suites serving thousands of outpatients daily.

While the Value and Dividend scores are more moderate at 2, Bumrungrad Hospital Pub Co‘s overall Momentum score of 4 further adds to its positive outlook. Investors looking for a company with high growth potential and a strong ability to withstand market fluctuations may find Bumrungrad Hospital Pub Co a promising long-term investment.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma